tetano
Editor, Senior Moderator
PLoS One. 2015 Apr 29;10(4):e0124593. doi: 10.1371/journal.pone.0124593. eCollection 2015.
[h=1]Delivery of GM-CSF to Protect against Influenza Pneumonia.[/h] Subramaniam R[SUP]1[/SUP], Hillberry Z[SUP]1[/SUP], Chen H[SUP]1[/SUP], Feng Y[SUP]1[/SUP], Fletcher K[SUP]1[/SUP], Neuenschwander P[SUP]2[/SUP], Shams H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Since adaptive immunity is thought to be central to immunity against influenza A virus (IAV) pneumonias, preventive strategies have focused primarily on vaccines. However, vaccine efficacy has been variable, in part because of antigenic shift and drift in circulating influenza viruses. Recent studies have highlighted the importance of innate immunity in protecting against influenza.
[h=4]METHODS:[/h] Granulocyte-macrophage colony stimulating factor (GM-CSF) contributes to maturation of mononuclear phagocytes, enhancing their capacity for phagocytosis and cytokine production.
[h=4]RESULTS:[/h] Overexpression of granulocyte macrophage-colony stimulating factor (GM-CSF) in the lung of transgenic mice provides remarkable protection against IAV, which depends on alveolar macrophages (AM). In this study, we report that pulmonary delivery of GM-CSF to wild type young and aged mice abrogated mortality from IAV.
[h=4]CONCLUSION:[/h] We also demonstrate that protection is species specific and human GM-CSF do not protect the mice nor stimulates mouse immunity. We also show that IAV-induced lung injury is the culprit for side-effects of GM-CSF in treating mice after IAV infection, and introduce a novel strategy to deliver the GM-CSF to and retain it in the alveolar space even after IAV infection.
PMID: 25923215 [PubMed - in process] Free full text
[h=1]Delivery of GM-CSF to Protect against Influenza Pneumonia.[/h] Subramaniam R[SUP]1[/SUP], Hillberry Z[SUP]1[/SUP], Chen H[SUP]1[/SUP], Feng Y[SUP]1[/SUP], Fletcher K[SUP]1[/SUP], Neuenschwander P[SUP]2[/SUP], Shams H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Since adaptive immunity is thought to be central to immunity against influenza A virus (IAV) pneumonias, preventive strategies have focused primarily on vaccines. However, vaccine efficacy has been variable, in part because of antigenic shift and drift in circulating influenza viruses. Recent studies have highlighted the importance of innate immunity in protecting against influenza.
[h=4]METHODS:[/h] Granulocyte-macrophage colony stimulating factor (GM-CSF) contributes to maturation of mononuclear phagocytes, enhancing their capacity for phagocytosis and cytokine production.
[h=4]RESULTS:[/h] Overexpression of granulocyte macrophage-colony stimulating factor (GM-CSF) in the lung of transgenic mice provides remarkable protection against IAV, which depends on alveolar macrophages (AM). In this study, we report that pulmonary delivery of GM-CSF to wild type young and aged mice abrogated mortality from IAV.
[h=4]CONCLUSION:[/h] We also demonstrate that protection is species specific and human GM-CSF do not protect the mice nor stimulates mouse immunity. We also show that IAV-induced lung injury is the culprit for side-effects of GM-CSF in treating mice after IAV infection, and introduce a novel strategy to deliver the GM-CSF to and retain it in the alveolar space even after IAV infection.
PMID: 25923215 [PubMed - in process] Free full text